Clinical and Laboratory Features of CD5-Negative Chronic Lymphocytic Leukemia
Clinical and Laboratory Features of CD5-Negative Chronic Lymphocytic Leukemia
复制标题
DOI：
10.12659/msm.901781
复制
发表时间：
2017-05-05
影响因子：
3.1
通讯作者：
Ebinc, Senar
中科院分区：
文献类型：
--
作者：
Demir, Cengiz;Kara, Erdal;Ebinc, Senar
背景：慢性淋巴细胞白血病（CLL）通常表达CD5抗原。然而，7-20%的患者是CD5阴性。我们报告了19例cd5阴性的B-CLL病例。材料/方法：回顾我院2009 - 2015年连续19例cd5阴性B-CLL病例，并与105例cd5阳性B-CLL病例进行比较。比较两组患者的临床参数、实验室参数和生存特征。结果：cd5阴性组淋巴结病变发生率为31.5%，cd5阳性组为51.4% （p=0.029）。cd5阴性组脾肿大发生率为42.1%，cd5阳性组为16.1% （p=0.029）。两组间Binet A、B、C期差异无统计学意义（p=0.118、p=0.051、p=0.882）。CD5阴性组和CD5阳性组中位血小板计数分别为144x10(9)/L和160x10(9)/L （p=0.044）。两组中位中性粒细胞计数无差异（p=0.169）。cd5阴性组和cd5阳性组平均淋巴细胞计数分别为43.2 +/- 4.0 × 10(9)/L和36.7 +/- 3.2 × 10(9)/L （p=0.001）。在自身免疫性溶血性贫血和自身免疫性血小板减少方面，两组之间没有差异。随访5年，cd5阴性患者生存率为84.2%，cd5阳性患者生存率为90.5% （p=0.393）。结论：在cd5阴性组中，我们发现更多的孤立性脾肿大，更少的淋巴结病变，更高的淋巴细胞计数和更低的血小板计数。两组在临床分期、自身免疫现象、血红蛋白和中性粒细胞计数、生存率方面均无差异。
Background: Chronic lymphocytic leukemia (CLL) usually expresses CD5 antigen. However, 7-20% of patients are CD5 negative. We report here a series of 19 CD5-negative B-CLL cases.Material/Methods: We reviewed 19 consecutive CD5-negative B-CLL cases seen in our medical center from 2009 to 2015 and compared them with 105 CD5-positive B-CLL cases. The two groups were compared in terms of clinical parameters, laboratory parameters, and survival characteristics.Results: Lymphadenopathy was present in 31.5% of the CD5-negative group and 51.4% of the CD5-positive group (p=0.029). Splenomegaly was present in 42.1% of the CD5-negative group and 16.1% of the CD5-positive group (p=0.029). There was no difference between the groups in terms of Binet A, B, and C stages (p=0.118, p=0.051, and p=0.882, respectively). The median thrombocyte count was 144x10(9)/L and 160x10(9)/L in the CD5- negative and CD5- positive groups, respectively (p=0.044).There was no difference between the two groups in terms of median neutrophil count (p=0.169). The mean lymphocyte count was 43.2 +/- 4.0x10(9)/L and 36.7 +/- 3.2x10(9)/L in the CD5-negative and CD5-positive groups, respectively (p=0.001). There was no difference between the groups in terms of autoimmune hemolytic anemia and autoimmune thrombocytopenia. In five-year follow-up, 84.2% of CD5-negative patients and 90.5% of CD5-positive patients were alive (p=0.393).Conclusions: We found more isolated splenomegaly, less lymphadenopathy, a higher lymphocyte count, and a lower thrombocyte count in the CD5-negative group. There was no difference between the groups in terms of clinical stage, autoimmune phenomena, hemoglobin and neutrophil count, and survival.